Vasculitis & polymyalgia rheumatica
Hydralazine Use and Risk of Vasculitis
Authors' conclusion
In this cohort study of adults who were newly prescribed hydralazine, vasculitis associated with hydralazine was rare, despite multiple reported cases.
Study context
- Population
- Adults 66 years or older, Ontario, Canada, newly prescribed hydralazine 2008–2021
- Participants
- 583,136 adults
- Exposure
- Hydralazine vs ACE inhibitor or angiotensin receptor blocker (ARB)
- Hydralazinen = 40,748
- ACE or ARBn = 542,388reference
- Outcome
- Diagnosis of vasculitis (ICD-10 codes)
Methodological detailspopulation-based, overlap-weighted Cox proportional hazards regression, active comparator
- Population-based
- Overlap-weighted Cox proportional hazards regression
- Active comparator
Main finding
As reported in the abstract
New-onset vasculitis · during follow-up
Each group vs ACE or ARBHazard ratio (95% CI)
Hydralazine
1.19(1.04–1.37)
- Hydralazine
- absolute risk difference 0.3 percentage points
Observational data: associations, not effects.
Further findings
Vasculitis accounting for competing risk of death
- Results no longer significant when accounting for the competing risk of death
Original publication
Hydralazine Use and Risk of Vasculitis. JAMA Netw Open. Published 2 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →